The information on this page is updated via a feed from the London Stock Exchange's Regulatory News Service.
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Report of Foreign
Issuer
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of
1934
For March 2009
Commission File
Number: 001-11960
AstraZeneca PLC
15 Stanhope Gate, London W1K 1LN, England
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form
40-F.
Form 20-F X
Form
40-F __
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7): ______
Indicate by check mark whether the
registrant by furnishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the
file number assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Press release entitled, “FDA
approves SYMBICORT for chronic obstructive pulmonary disease”, dated 2
March 2009.
2.
Press release entitled,
“Publication of Annual Report”, dated 4 March
2009.
3.
Press release entitled, “Filing of
Annual Report on Form 20-F with the US Securities and Exchange
Commission”, dated 17 March
2009.
4.
Press release entitled,
“AstraZeneca PLC Annual Information Update”, dated 20 March
2009.
5.
Press release entitled,
“Transaction by Persons Discharging Managerial Responsibilities Disclosure
Rule DTR 3.1.4 ”, dated 25 March
2009.
6.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4 “, dated 25 March
2009.
7.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4”, dated 30 March
2009.
8.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4”, dated 30 March
2009.
9.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4”, dated 30 March
2009.
10.
Press release entitled,
“Transaction by
Persons Discharging Managerial Responsibilities Disclosure Rule DTR
3.1.4”, dated 30
March 2009.
11.
Press release entitled,
“Transaction
Directive Voting Rights and Capital”, dated 31 March
2009.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
AstraZeneca
PLC
Date: 2 April
2009
By:
/s/ Justin
Hoskins
Name:
Justin
Hoskins
Title:
Deputy Company
Secretary
Item 1
FDA
APPROVES SYMBICORT FOR CHRONIC OBSTRUCTIVE
PULMONARY
DISEASE
AstraZeneca today
announced that the U.S. Food and
Drug Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate
dihydrate) 160/4.5 mcg for
the twice daily maintenance treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD), including chronic bronchitis and
emphysema.
The FDA approval is
based on results from two pivotal clinical trials, SHINE (6-month) and SUN
(12-month), which found SYMBICORT significantly improved lung function within
five minutes of the first dose and sustained that lung function improvement for
the duration of the studies. SYMBICORT pMDI (pressurized
metered-dose inhaler) has been
available in the U.S. since June 2007 for the
long-term maintenance treatment of asthma in patients 12 years of age and
older.
“More than 12
million Americans with COPD struggle each day to live with the debilitating
symptoms of COPD,” said
Dr. Howard Hutchinson, Chief Medical Officer, AstraZeneca. “With the approval of
SYMBICORT in COPD, patients have a new treatment option that can deliver
long-term lung function improvement and daily symptom control, together with a
rapid onset of action.”
COPD is a disorder
encompassing two serious lung diseases – emphysema and chronic bronchitis –
which result in chronic airway inflammation and progressive loss of lung
function, making it difficult to breathe normally.
About SYMBICORT
Symbicort is
approved for use in the treatment of COPD in 91 countries
worldwide.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and supplier
for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infectious disease medicines. For more information about
AstraZeneca, please visit: www.astrazeneca.com
Media
Enquiries UK:
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 20 7304
5045 (24 hours)
Sarah
Lindgreen
+44 20 7304
5033 (24 hours)
Media
Enquires US:
Katie
Neff
+1 302 885
9960
Emily
Denney
+1 302 885
3451
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
2
March 2009
- ENDS
-
Item 2
PUBLICATION
OF ANNUAL REPORT
AstraZeneca PLC
announced today the publication of its Annual Report and Form 20-F Information
2008, Notice of Annual General Meeting 2008 and Shareholders’ Circular, and
Letter from the Chairman and AstraZeneca 2008 in brief. Copies of the
documents have been filed with the UK Listing Authority in accordance with Rule
9.6.1 of the Listing Rules and will be available for viewing at the UKLA
document viewing facility at 25 The North Colonnade, Canary Wharf, London E14
5HS. The documents are also available on the Company's website
www.astrazeneca.com and will be despatched to shareholders shortly.
A C N
Kemp
Company
Secretary
4 March
2009
Item 3
FILING
OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE
COMMISSION
AstraZeneca PLC
announced today that, on 17 March 2009, it filed its Annual Report on Form 20-F
with the US Securities and Exchange Commission (SEC). The document is
available for viewing on the SEC website at www.sec.gov
and also on the Company’s website at www.astrazeneca.com. The
Company will send any holder of the Company’s securities, upon request, a hard
copy of the Company’s complete audited financial statements free of
charge. Requests may be made by writing to the Company Secretary,
AstraZeneca PLC, 15 Stanhope Gate, London W1K 1LN.
A C N
Kemp
Company
Secretary
17 March
2009
Item 4
ASTRAZENECA
PLC
ANNUAL
INFORMATION UPDATE
As required under the Prospectus
(Directive 2003/71/EC) Regulations 2005 and paragraph 5.2 of the Prospectus
Rules, and following
publication of the Annual Report and Form 20-F Information on 4 March
2009, AstraZeneca PLC is
presenting its Annual Information Update in relation to information that has
been published or made available to the public between 22 May 2008 and 19
March 2009.
This Annual
Information Update is also being made available on the Investors section of our
website, www.astrazeneca.com.
The information
referred to in this Annual Information Update was correct at the time it was
published but may now be out of date.
1.
Announcements made via a RIS
The documents
listed below were published via a Regulatory Information Service on or around
the dates indicated.
Date
Description
of Contents of Announcement
22/05/08
Supplementary
Prospectus
22/05/08
Annual
Information Update
23/05/08
Director/PDMR
Shareholding
30/05/08
Total Voting
Rights
04/06/08
Symbicort
sNDA
05/06/08
Transaction
in Own Shares
10/06/08
Transaction
in Own Shares
11/06/08
Transaction
in Own Shares
12/06/08
Transaction
in Own Shares
13/06/08
Transaction
in Own Shares
16/06/08
Transaction
in Own Shares
18/06/08
Transaction
in Own Shares
19/06/08
Transaction
in Own Shares
23/06/08
Transaction
in Own Shares
26/06/08
Transaction
in Own Shares
27/06/08
Transaction
in Own Shares
30/06/08
Total Voting
Rights
30/06/08
EuroBond
02/07/08
Seroquel
Judgment
09/07/08
EuroBond
23/07/08
Saxagliptin
30/07/08
Notice of
Results
31/07/08
Total Voting
Rights
05/08/08
BuyBack
Programme Notice
07/08/08
Transaction
in Own Shares
08/08/08
Transaction
in Own Shares
11/08/08
Transaction
in Own Shares
12/08/08
Transaction
in Own Shares
13/08/08
Transaction
in Own Shares
14/08/08
Transaction
in Own Shares
15/08/08
Transaction
in Own Shares
18/08/08
Transaction
in Own Shares
18/08/08
Director/PDMR
Shareholding
19/08/08
Transaction
in Own Shares
20/08/08
Transaction
in Own Shares
21/08/08
Transaction
in Own Shares
22/08/08
Transaction
in Own Shares
26/08/08
Transaction
in Own Shares
27/08/08
Transaction
in Own Shares
28/08/08
Transaction
in Own Shares
29/08/08
Transaction
in Own Shares
29/08/08
Total Voting
Rights
01/09/08
Transaction
in Own Shares
02/09/08
Transaction
in Own Shares
03/09/08
Transaction
in Own Shares
04/09/08
Transaction
in Own Shares
05/09/08
Transaction
in Own Shares
08/09/08
Transaction
in Own Shares
09/09/08
Transaction
in Own Shares
10/09/08
Transaction
in Own Shares
11/09/08
Transaction
in Own Shares
12/09/08
Transaction
in Own Shares
12/09/08
Directorate
Change [RM]
15/09/08
Transaction
in Own Shares
16/09/08
Transaction
in Own Shares
16/09/08
Research
Update : AZD3480
17/09/08
Transaction
in Own Shares
18/09/08
Transaction
in Own Shares
19/09/08
Transaction
in Own Shares
22/09/08
Transaction
in Own Shares
23/09/08
Transaction
in Own Shares
24/09/08
Transaction
in Own Shares
24/09/08
Pulmicort
Patent Litigation
25/09/08
Transaction
in Own Shares
26/09/08
Transaction
in Own Shares
29/09/08
Transaction
in Own Shares
30/09/08
Transaction
in Own Shares
30/09/08
Transaction
in Own Shares : Notice of Additional Day
30/09/08
Total Voting
Rights
01/10/08
Transaction
in Own Shares
02/10/08
Transaction
in Own Shares
17/10/08
AstraZeneca
and Pozen PN400
29/10/08
Notice of
Results
31/10/08
Total Voting
Rights
04/11/08
Directorate
Change [JSP]
10/11/08
Jupiter Trial
Results
13/11/08
Seroquel EU
Approval
19/11/08
Pulmicort
19/11/08
Pulmicort
Respules
19/11/08
Zactima
20/11/08
Pulmicort
Respules – Teva TRO
25/11/08
CoPromotion
of Abraxane
26/11/08
Pulmicort
Respules - Settlement
28/11/08
Motavizumab
28/11/08
Total Voting
Rights
03/12/08
PN 400 Phase
III
08/12/08
AstraZeneca
and BMS : Dapagliflozin
09/12/08
AstraZeneca
and Targacept : AZD3480
11/12/08
Return of
Rights to Infinity Pharmaceuticals
12/12/08
Symbicort –
FDA LABA
19/12/08
Project
Compass
24/12/08
Seroquel XR –
FDA Letter
05/01/09
Total Voting
Rights
22/01/09
Director’s
Dealing : Pledge of Shares
28/01/09
Notice of
Results
29/01/09
Q4 and Year
End Results
29/01/09
Currency
Sensitivity Guide
29/01/09
AstraZeneca
and Pozen : PN400 Trials
30/01/09
Total Voting
Rights
24/02/09
AZ & MAP
Pharmaceuticals : Budesonide
25/02/09
FDA PDAC re
Seroquel
25/02/09
PDMR
Interests [DBR+JSP]
25/02/09
PDMR
Interests [BA+JL]
26/02/09
PDMR
Interests [SET]
26/02/09
PDMR
Interests [SJL+JSP]
26/02/09
PDMR
Interests [DRB]
27/02/09
Seroquel XR :
FDA CRL
27/02/09
Directorate
Change [HM]
27/02/09
Total Voting
Rights
02/03/09
Symbicort
COPD
04/03/09
Annual Report
and Accounts 2008
17/03/09
Notice re
20F
All of the above
documents are available for download on the Prices and News section of the
London Stock Exchange website, www.londonstockexchange.com.
2.
Documents filed at Companies House
All of the
documents below were filed with the Registrar of Companies in England and Wales
on or around the dates indicated.
Date
Document
type
06/06/08
Group of
Companies’ Accounts made up to 31/12/07
16/06/08
Interim
Accounts made up to 31/03/08
23/06/08
Form 363 –
Return made up to 15/05/08
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
10/07/08
Form 169 –
Return by a Company Purchasing its Own Shares
18/08/08
Interim
Accounts made up to 30/06/08
19/11/08
Interim
Accounts made up to 30/09/08
05/12/08
Form 288a –
Director Appointed
06/01/09
Form 288b –
Secretary Resigned
06/01/09
Form 288a –
Secretary Appointed
19/01/09
Form 353a –
Location of Register of Members
All of the
documents above are available for download from the Companies House website at
www.companieshouse.gov.uk,
or can be obtained from Companies House, Crown Way, Maindy, Cardiff, CF14
3UZ.
3.
Documents submitted to the FSA
All the documents
below were submitted to the FSA on or around the dates indicated.
Date
Document
04/03/09
Annual Report
and Form 20-F Information 2008
04/03/09
Notice of AGM
2009 and Shareholders’Circular
04/03/09
Shareholder
Letter 2009
Documents submitted
to the FSA can be viewed at the Document Viewing Facility situated at The
Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14
5HS.
The Notice of AGM,
Annual Report and Form 20-F Information and Shareholder Letter are also
available via the Investors section of our website, www.astrazeneca.com.
4.
Documents lodged with the Securities and Exchange Commission
The documents
listed below were filed with the SEC on or around the dates
indicated.
Date
Document
19/06/08
Form 6-K
Quarterly Reports
24/06/08
Form
11-K
09/07/08
Form 6-K
Quarterly Reports
05/08/08
Form 6-K
Quarterly Reports
05/08/08
Form
S-8
05/09/08
Form 6-K
Quarterly Reports
02/10/08
Form 6-K
Quarterly Reports
05/11/08
Form 6-K
Quarterly Reports
04/12/08
Form 6-K
Quarterly Reports
12/01/09
Form 6-K
Quarterly Reports
06/02/09
Form 6-K
Quarterly Reports
03/03/09
Form 6-K
Quarterly Reports
17/03/09
Form 20-F
Annual Report
All of the
documents above are available for viewing on the Investor section of our
website, www.astrazeneca.com.
5. Further
Information
Further information
about AstraZeneca PLC can be found at our website, www.astrazeneca.com.
Item 5
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 24 March 2009, the interest of the following Directors in
AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed
below. The change in interest relates to the vesting of previously
announced awards made in March 2006 under the AstraZeneca Performance Share Plan
whereby, following the application of performance measures specified at the time
of grant, the individuals concerned have now become beneficially entitled to 89%
of the shares originally awarded. In accordance with the plan rules,
the unvested part of the award has immediately and irrevocably
lapsed. In each case, sufficient vested shares were withheld to cover
certain tax obligations arising on the vesting.
Name of
Director
Number of
Shares Awarded
Number of
Shares Lapsed
Number of
Shares Vested
Number of
Shares Withheld
Net Number of
Shares
Current
Holding
Percentage of
Issued Share Capital
David R
Brennan
73,109
8,042
65,067
26,678
38,389
See
below
See
below
John
Patterson
32,319
3,555
28,764
11,794
16,970
144,353
0.01%
Mr
Brennan has interests in both the Ordinary Shares and the American Depositary
Shares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary
Share.
As a result of this
transaction, Mr Brennan’s interest is now 376,641 Ordinary Shares and 76,188
AstraZeneca ADSs, which together represent approximately 0.031% of the Company’s
issued ordinary capital.
The market price of
AstraZeneca PLC Ordinary Shares of $0.25 each on 24 March 2009 was 2287
pence.
A
C N Kemp
Company
Secretary
25
March 2009
Item 6
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 24 March 2009, the interest of the following individuals, who are
all persons discharging managerial responsibilities, in AstraZeneca PLC Ordinary
Shares of $0.25 each, changed as detailed below. The change in
interest relates to the vesting of previously announced awards made in March
2006 under the AstraZeneca Performance Share Plan or, for Jeff Pott and Lynn
Tetrault, the AstraZeneca Executive Performance Share Plan, whereby, following
the application of performance measures specified at the time of grant, the
individuals concerned have now become beneficially entitled to a percentage of
the shares originally awarded. In accordance with the plan rules, the
unvested part of the award has immediately and irrevocably lapsed. In
each case, sufficient vested shares were withheld to cover certain tax
obligations arising on the vesting. The interests of Jeff Pott, Lynn
Tetrault and Tony Zook are in the Company’s American Depositary Shares
(ADSs). One ADS equals one Ordinary Share.
Name
Number of
Shares Awarded
Vesting
Percentage
Number of
Shares Lapsed
Number of
Shares Vested
Number of
Shares Withheld
Net Number of
Shares
Bruno
Angelici
26,781
89%
2,946
23,835
9,773
14,062
Jan
Lundberg
18,475
89%
2,032
16,443
9,537
6,906
Jeff
Pott
2,020
75%
505
1,515
490
1,025
Lynn
Tetrault
4,221
75%
1,055
3,166
1,025
2,141
Tony
Zook
37,624
89%
4,139
33,485
14,197
19,288
The market price of
AstraZeneca PLC Ordinary Shares of $0.25 each on 24 March 2009 was 2287
pence. The market price of AstraZeneca ADSs on 24 March 2009 was
$33.31.
A
C N Kemp
Company
Secretary
25
March 2009
Item 7
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rules DTR 3.1.4R
We hereby inform
you that on 27 March 2009 the following Directors of AstraZeneca PLC were
granted options under the AstraZeneca Share Option Plan over the Company’s
USD0.25 Ordinary Shares.
Name of
Director
Number of
shares over which option is granted
Exercise
price per share
Period when
exercisable
Total number
of shares under option
D R
Brennan
160,016
2280p
27.3.12-26.3.19
See
below
S
Lowth
65,131
2280p
27.3.12-26.3.19
153,934
The options will
become exercisable on 27 March 2012 subject to certain performance
conditions. The conditions, which will not be subject to any
retesting, are that the earnings per share of the Company must increase by the
increase in the UK Retail Prices Index plus 5% per annum on average over three
years, and that no significant unforeseen event has taken place which, in the
reasonable opinion of the Remuneration Committee, has resulted in major
reputational damage to AstraZeneca, and the circumstances of which are
exceptional enough to justify the option not vesting and becoming
exercisable. Failure to satisfy either or both of these conditions
will result in the lapse of the option in its entirety.
David R Brennan, a
Director of the Company, has previously received grants of options over the
Company’s American Depositary Shares (ADSs). One ADS equals one
Ordinary Share. Following the grant of options referred to above,
David Brennan has options over 592,975 Ordinary Shares and 355,246
ADSs.
A
C N Kemp
Company
Secretary
30
March 2009
Item 8
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rules DR 3.1.4R
We hereby inform
you that on 27 March 2009 the following Directors of AstraZeneca PLC were each
granted an award under the terms of the AstraZeneca Performance Share Plan over
the Company’s USD0.25 Ordinary Shares.
Name of
Director
Target number
of shares awarded
Award price
per share
Normal
vesting date
Total
interest in shares after this award
Percentage of
shares in issue
D R
Brennan
133,347
2280p
27 March
2012
See
below
See
below
S
Lowth
54,276
2280p
27 March
2012
140,243
0.01%
The AstraZeneca
Performance Share Plan was approved by shareholders at the Company’s AGM in
2005. Awards made under the Plan may not generally vest before the
third anniversary of the relevant date of grant nor unless the specified
performance target(s) have been met at the end of the three year period which,
for this award, is 1 January 2009 to 31 December 2011.
The performance
target that applies to this award is the Company’s Total Shareholder Return
(“TSR”) compared to the TSR of a selected peer group of 12 other pharmaceutical
companies. The actual number of shares to which a participant may
become unconditionally entitled will depend on the extent to which the
performance target(s) have been met. A summary of the Plan, including
a more detailed explanation of the performance target(s), can be found in the
AstraZeneca Annual Report and Form 20-F Information 2008 which is available on
the Company’s website www.astrazeneca.com.
Mr Brennan has
interests in the Company’s Ordinary Shares and American Depositary Shares
(ADSs). One ADS equals one Ordinary Share. In total, Mr
Brennan now has an interest in 509,988 Ordinary Shares and 76,188 ADSs, which
together represent approximately 0.04% of the number of shares currently in
issue.
A
C N Kemp
Company
Secretary
30
March 2009
Item 9
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rules DTR 3.1.4R
We hereby inform
you that on 27 March 2009 the following individuals, who are all persons
discharging managerial responsibilities, were granted options under the
AstraZeneca Share Option Plan over the Company’s USD0.25 Ordinary Shares or, in
the case of L Tetrault and A Zook, over the Company’s American Depositary Shares
(ADSs). One ADS equals one Ordinary Share
Name of
individual
Number of
shares over which option is granted
Exercise
price per share
Period when
exercisable
B
Angelici
40,964
2280p
27.3.12-26.3.19
A
Ekblom
30,180
2280p
27.3.12-26.3.19
J
Lundberg
41,668
2280p
27.3.12-26.3.19
J
Pott
30,701
2280p
27.3.12-26.3.19
D
Smith
33,333
2280p
27.3.12-26.3.19
L
Tetrault
73,926
US$33.39
27.3.12-26.3.19
A
Zook
113,638
US$33.39
27.3.12-26.3.19
The options will
become exercisable on 27 March 2012 subject to certain performance
conditions. The conditions, which will not be subject to any
retesting, are that the earnings per share of the Company must increase by the
increase in the UK Retail Prices Index plus 5% per annum on average over three
years, and that no significant unforeseen event has taken place which, in the
reasonable opinion of the Remuneration Committee, has resulted in major
reputational damage to AstraZeneca, and the circumstances of which are
exceptional enough to justify the option not vesting and becoming
exercisable. Failure to satisfy either or both of these conditions
will result in the lapse of the option in its entirety.
A
C N Kemp
Company
Secretary
30
March 2009
Item 10
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rules DR 3.1.4R
We hereby inform
you that on 27 March 2009, the following individuals, who are all persons
discharging managerial responsibilities, were each granted an award under the
terms of the AstraZeneca Performance Share Plan over the Company’s USD0.25
Ordinary Shares or, in the case of L Tetrault and A Zook, over the Company’s
American Depositary Shares (ADSs). One ADS equals one Ordinary
Share
Name of
individual
Target number
of shares awarded
Award price
per share
Normal
vesting date
B
Angelici
30,723
2280p
27 March
2012
A
Ekblom
22,635
2280p
27 March
2012
J
Lundberg
31,251
2280p
27 March
2012
J
Pott
23,026
2280p
27 March
2012
D
Smith
25,000
2280p
27 March
2012
L
Tetrault
55,444
US$33.39
27 March
2012
A
Zook
85,229
US$33.39
27 March
2012
The AstraZeneca
Performance Share Plan was approved by shareholders at the Company’s AGM in
2005. Awards made under the Plan may not generally vest before the
third anniversary of the relevant date of grant nor unless the specified
performance target(s) have been met at the end of the three year period which,
for this award, is 1 January 2009 to 31 December 2011.
The performance
target that applies to this award is the Company’s Total Shareholder Return
(“TSR”) compared to the TSR of a selected peer group of 12 other pharmaceutical
companies. The actual number of shares to which a participant may
become unconditionally entitled will depend on the extent to which the
performance target(s) have been met. A summary of the Plan, including
a more detailed explanation of the performance target(s), can be found in the
AstraZeneca Annual Report and Form 20-F Information 2008 which is available on
the Company’s website www.astrazeneca.com.
A
C N Kemp
Company
Secretary
30
March 2009
Item 11
Transparency
Directive
Voting
Rights and Capital
The following
notification is made in accordance with the UK Financial Services Authority
Disclosure and Transparency Rule 5.6.1. On 31 March 2009 the
issued share capital of AstraZeneca PLC with voting rights is 1,447,650,718
ordinary shares of US$0.25. No shares are held in Treasury.
Therefore, the total number of voting rights in AstraZeneca PLC is
1,447,650,718.
The above figure
for the total number of voting rights may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
AstraZeneca PLC under the FSA's Disclosure and Transparency Rules.
A
C N Kemp
Company
Secretary
31
March 2009
